Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:13 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Lidocaine Subcutaneous Infusion for Control of Treprostinil Related Site Pain
NCT01433328 · Jewish General Hospital · PHASE4 · terminated · last registry update 2023-02-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Safety considerations” | – | Registry record, Jewish General Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SCN1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-01-31Results posted on the registry: The University of Texas Health Science Center, Houston, a drug against SCN1A (NCT05631548)
- 2024-01-16Results posted on the registry: UCB Biopharma SRL, Brivaracetam (BRV) intravenous (iv) + Brivaracetam (BRV) oral (NCT03325439)
- 2024-01-05Results posted on the registry: The University of Texas Health Science Center, Houston, Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg) + Placebo (NCT03854019)
- 2023-11-15Results posted on the registry: Wake Forest University Health Sciences, a drug against SCN1A (NCT05439421)
- 2023-11-03Results posted on the registry: Temple University, Clavulanic acid + Intravenous cocaine (NCT02563769)
- 2023-10-06Results posted on the registry: Yale University, Cocaine Self-adminstration (NCT03471182)
- 2023-08-28Results posted on the registry: Georgetown University, SM-88 (NCT04720664)
- 2023-08-28Also stopped (terminated): Georgetown University, SM-88 (NCT04720664)
- 2023-08-14Results posted on the registry: Glenn-Milo Santos, lorcaserin + Placebo Oral Tablet (NCT03192995)
- 2023-08-14Also stopped (terminated): Glenn-Milo Santos, lorcaserin + Placebo Oral Tablet (NCT03192995)
- 2023-08-14Also stopped (terminated): Yale University, Calcitriol (NCT04826133)
- 2023-07-19Results posted on the registry: Baylor College of Medicine, placebo + disulfiram (NCT00729300)
- 2023-07-11Phase 3 first posted: Region Örebro County, dronedarone - Multaq™ OR flecainide - Tambocor™ OR propafenone - Rytmonorm™ OR sotalol - Sotacor™ (NCT05939076)
- 2023-07-03Phase 3 first posted: Sintetica SA, Chloroprocaine 3% eye gel + Oxybuprocaine Hydrochloride 4 Mg/mL Eye Drops (NCT05926258)
- 2023-06-23Results posted on the registry: Noel Jabbour, a drug against SCN1A (NCT03868891)
- 2023-06-23Also stopped (terminated): Noel Jabbour, a drug against SCN1A (NCT03868891)
- 2023-06-22Results posted on the registry: Temple University, Clavulanic Acid (NCT04411914)
- 2023-05-15Results posted on the registry: Yale University, a drug against SCN1A (NCT04418076)
- 2023-04-04Also stopped (terminated): Escola Superior de Ciencias da Saude, a drug against SCN1A (NCT04226144)
- 2023-03-13Phase 3 first posted: Friends Research Institute, Inc., Methadone Treatment-As-Usual (NCT05766631)
- 2023-03-08Results posted on the registry: University of Florida, dextromethorphan HBr and quinidine sulfate (NCT03883581)
- 2023-03-02Also stopped (terminated): M. Carmen Cabellos Minguez, Phenytoin + placebo (NCT01478035)
- 2023-02-16Also stopped (terminated): Yale University, Methylphenidate + Alpha Methyl Para Tyrosine (AMPT) (NCT02152670)
- 2023-02-13Results posted on the registry: Otsuka Pharmaceutical Development & Commercialization, Inc., AVP-786 + Placebo (NCT02442765)
- 2023-02-10Results posted on the registry: Medical University of South Carolina, a drug against SCN1A (NCT03681769)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision